[go: up one dir, main page]

EA202092122A1 - Антитела против tip-1 и их применения - Google Patents

Антитела против tip-1 и их применения

Info

Publication number
EA202092122A1
EA202092122A1 EA202092122A EA202092122A EA202092122A1 EA 202092122 A1 EA202092122 A1 EA 202092122A1 EA 202092122 A EA202092122 A EA 202092122A EA 202092122 A EA202092122 A EA 202092122A EA 202092122 A1 EA202092122 A1 EA 202092122A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
antibodies against
application
against tip
methods
Prior art date
Application number
EA202092122A
Other languages
English (en)
Inventor
Минхань Ван
Хой Цзоу
Джошуа Оукс
Original Assignee
Фейнз Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фейнз Терапьютикс, Инк. filed Critical Фейнз Терапьютикс, Инк.
Publication of EA202092122A1 publication Critical patent/EA202092122A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Описаны антитела против TIP-1 и их антигенсвязывающие фрагменты. Описаны также нуклеиновые кислоты, кодирующие антитела, композиции, содержащие антитела, способы получения антител и способы применения антител для лечения или предотвращения заболеваний, таких как злокачественная опухоль.
EA202092122A 2018-03-08 2019-03-06 Антитела против tip-1 и их применения EA202092122A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862640123P 2018-03-08 2018-03-08
PCT/US2019/020867 WO2019173417A1 (en) 2018-03-08 2019-03-06 Anti-tip-1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA202092122A1 true EA202092122A1 (ru) 2020-12-03

Family

ID=67845760

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092122A EA202092122A1 (ru) 2018-03-08 2019-03-06 Антитела против tip-1 и их применения

Country Status (9)

Country Link
US (1) US11306151B2 (ru)
EP (1) EP3762028A4 (ru)
JP (1) JP2021514662A (ru)
KR (1) KR20200129108A (ru)
CN (1) CN111886024B (ru)
AU (1) AU2019232759A1 (ru)
CA (1) CA3089649A1 (ru)
EA (1) EA202092122A1 (ru)
WO (1) WO2019173417A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021126538A1 (en) * 2019-12-17 2021-06-24 Phanes Therapeutics, Inc. Bispecific antibodies with alternatively matched interchain cycteines and uses thereof
US20240317885A1 (en) * 2021-07-16 2024-09-26 Medical Guidance Systems, Llc Anti-tax interacting protein-1 (tip1) binding molecules
CN114656549A (zh) * 2022-05-10 2022-06-24 南开大学 基于tip-1-多肽相互作用的新型分子胶水

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132596A0 (en) 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
JP2008517975A (ja) * 2004-10-25 2008-05-29 サイトス バイオテクノロジー アーゲー 胃酸分泌抑制ポリペプチド（ｇｉｐ）抗原アッセイ及びその使用
US20060275288A1 (en) * 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
PL2406284T3 (pl) * 2009-03-10 2017-09-29 Biogen Ma Inc. Przeciwciała anty-bcma
KR101138460B1 (ko) * 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
WO2013081993A1 (en) * 2011-12-02 2013-06-06 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
JP2013138638A (ja) * 2011-12-28 2013-07-18 Meneki Seibutsu Kenkyusho:Kk 抗活性型ｇｉｐ抗体及びその利用
PL2958943T3 (pl) * 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
EP3172237A2 (en) * 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
SG11201701711VA (en) * 2014-09-16 2017-04-27 Regeneron Pharma Anti-glucagon antibodies and uses thereof
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP6737592B2 (ja) * 2014-12-22 2020-08-12 花王株式会社 抗活性型ｇｉｐ抗体
JP6861641B2 (ja) * 2015-04-02 2021-04-21 アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ グルカゴン受容体アンタゴニスト抗体を用いた肥満症および非アルコール性脂肪性肝疾患または非アルコール性脂肪性肝炎を治療するための方法
TWI790642B (zh) * 2015-06-05 2023-01-21 美商建南德克公司 抗-tau抗體及使用方法

Also Published As

Publication number Publication date
CA3089649A1 (en) 2019-09-12
CN111886024A (zh) 2020-11-03
CN111886024B (zh) 2024-07-30
AU2019232759A1 (en) 2020-08-27
US11306151B2 (en) 2022-04-19
JP2021514662A (ja) 2021-06-17
KR20200129108A (ko) 2020-11-17
WO2019173417A1 (en) 2019-09-12
US20200399396A1 (en) 2020-12-24
EP3762028A1 (en) 2021-01-13
EP3762028A4 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
EA202092735A1 (ru) Антагонизирующее cd73 антитело
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
EA201991071A1 (ru) Композиции и способы для лечения ezh2-опосредованного рака
MX2022002682A (es) Anticuerpos anti-cd73.
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
EA201991546A1 (ru) Антигенсвязывающие белки против нейропилина и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA202091747A1 (ru) Составы антитела b7-h4
EA202190807A1 (ru) Антитела к синуклеину
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
EA202092122A1 (ru) Антитела против tip-1 и их применения
EA202192488A1 (ru) Антитела против tsg-6 и их применения
EA202090864A1 (ru) Моноклональное антитело к il-5r
EA202192254A1 (ru) Fcmr-связывающие молекулы и их применение
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками